Established safety profile in advanced NSCLC

Most common adverse reactions (ARs) (≥10%) for ABRAXANE + carboplatin observed at a similar incidence as with paclitaxel injection + carboplatin in the phase III trial

Most common adverse reactions in non-small cell lung cancer

Established safety profile in advanced NSCLC

Most common adverse reactions (ARs) (?10%) for ABRAXANE + carboplatin observed at a similar incidence as with paclitaxel injection + carboplatin in the phase III trial

Most common adverse reactions in non-small cell lung cancer

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.